Read this company snapshot
Daily valuation snapshot
Mesoblast Limited American Depositary Shares: source evidence dated 2026-10-09.
- Daily close (USD)
- $14.29
- Market capitalization (USD)
- $1,853,216,906.9
- Price / earnings (TTM)
- Not reported
- Price / book
- 3.26
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research MESO in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research MESO in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure; MPC-25-IC for the treatment or prevention of acute myocardial infarction; and Ryoncil for the treatment of pediatric SR-aGVHD; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing MESO with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $14.29 |
| Market capitalization (USD) | $1,853,216,906.9 |
| Price / earnings (TTM) | Not reported |
| Price / book | 3.26 |
No matching rows. Clear the filter to see all records.
Read MESO's valuation metrics
Company size
Mesoblast Limited American Depositary Shares's recorded market capitalization is $1,853,216,906.9. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
MESO's recorded price-to-book ratio is 3.26. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Mesoblast Limited American Depositary Shares with Aurora
Use the snapshot above to ask a specific question about MESO. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow MESO's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.